Join Growin Stock Community!

Bristol-myers squibb company ceCELG-RI.US Overview

US StockHealthcare
(No presentation for CELG-RI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CELG-RI AI Insights

CELG-RI Overall Performance

CELG-RI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CELG-RI Recent Performance

6.28%

Bristol-myers squibb company ce

-3.61%

Avg of Sector

-2.16%

S&P500

CELG-RI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CELG-RI Key Information

CELG-RI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CELG-RI Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Price of CELG-RI

CELG-RI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CELG-RI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
0.02
METRIC
VALUE
vs. INDUSTRY
Gross Margin
65.89%
Net Margin
14.64%
Revenue Growth (YoY)
-0.22%
Profit Growth (YoY)
-0.47%
3-Year Revenue Growth
3.11%
3-Year Profit Growth
-2.05%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
0.02
Gross Margin
65.89%
Net Margin
14.64%
Revenue Growth (YoY)
-0.22%
Profit Growth (YoY)
-0.47%
3-Year Revenue Growth
3.11%
3-Year Profit Growth
-2.05%
  • When is CELG-RI's latest earnings report released?

    The most recent financial report for Bristol-myers squibb company ce (CELG-RI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CELG-RI's short-term business performance and financial health. For the latest updates on CELG-RI's earnings releases, visit this page regularly.

  • Where does CELG-RI fall in the P/E River chart?

    According to historical valuation range analysis, Bristol-myers squibb company ce (CELG-RI)'s current price-to-earnings (P/E) ratio is 0.03, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of CELG-RI?

    According to the latest financial report, Bristol-myers squibb company ce (CELG-RI) reported an Operating Profit of 3.63B with an Operating Margin of 29.05% this period, representing a growth of 43.5% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CELG-RI's revenue growth?

    In the latest financial report, Bristol-myers squibb company ce (CELG-RI) announced revenue of 12.5B, with a Year-Over-Year growth rate of 1.3%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CELG-RI have?

    As of the end of the reporting period, Bristol-myers squibb company ce (CELG-RI) had total debt of 48.97B, with a debt ratio of -4.23. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CELG-RI have?

    At the end of the period, Bristol-myers squibb company ce (CELG-RI) held Total Cash and Cash Equivalents of 10.21B, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CELG-RI go with three margins increasing?

    In the latest report, Bristol-myers squibb company ce (CELG-RI) achieved the “three margins increasing” benchmark, with a gross margin of 91.77%%, operating margin of 28.06%%, and net margin of 8.69%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CELG-RI's profit trajectory and future growth potential.

  • Is CELG-RI's EPS continuing to grow?

    According to the past four quarterly reports, Bristol-myers squibb company ce (CELG-RI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CELG-RI?

    Bristol-myers squibb company ce (CELG-RI)'s Free Cash Flow (FCF) for the period is 1.6B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 60.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CELG-RI?

    The latest valuation data shows Bristol-myers squibb company ce (CELG-RI) has a Price-To-Earnings (PE) ratio of 0.03 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.